J&J’s multiple myeloma therapies drive oncology business despite slow Carvykti sales

John­son & John­son de­fend­ed slow­er-than-ex­pect­ed sales of Carvyk­ti in the first quar­ter, with ex­ecs say­ing they ex­pect sales of the cell ther­a­py to ac­cel­er­ate in the sec­ond half of the year.

The treat­ment brought in $157 mil­lion in sales in the first quar­ter, down from $159 mil­lion in the fourth quar­ter of last year. It had $72 mil­lion in sales in the first quar­ter of 2023.

In an in­vestor call on Tues­day morn­ing, J&J’s world­wide chair­man of in­no­v­a­tive med­i­cine Jen­nifer Taubert said the flat Carvyk­ti sales were due to “phas­ing and tim­ing of or­ders and when they were ac­tu­al­ly de­liv­ered and billed.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.